Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.

Shapiro A.

Expert Opin Biol Ther. 2013 Sep;13(9):1287-97. doi: 10.1517/14712598.2013.819339. Review.

PMID:
23930915
2.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.

J Thromb Haemost. 2015 Jun;13(6):967-77. doi: 10.1111/jth.12911. Epub 2015 Apr 23.

PMID:
25912075
3.

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.

Mancuso ME, Mannucci PM.

Drug Des Devel Ther. 2014 Mar 28;8:365-71. doi: 10.2147/DDDT.S47312. eCollection 2014. Review.

4.

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.

J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10.

5.

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.

Peters RT, Toby G, Lu Q, Liu T, Kulman JD, Low SC, Bitonti AJ, Pierce GF.

J Thromb Haemost. 2013 Jan;11(1):132-41. doi: 10.1111/jth.12076.

6.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF; B-LONG Investigators..

N Engl J Med. 2013 Dec 12;369(24):2313-23. doi: 10.1056/NEJMoa1305074. Epub 2013 Dec 4.

7.

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, Fraley C, Drager D, Reidy T, McCue J, Franck HW, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H.

Blood. 2012 Mar 29;119(13):3024-30. doi: 10.1182/blood-2011-08-367813. Epub 2012 Jan 13.

8.

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.

Powell J, Shapiro A, Ragni M, Negrier C, Windyga J, Ozelo M, Pasi J, Baker R, Potts J, Li S, Mei B, Pierce GF, Robinson B.

Br J Haematol. 2015 Jan;168(1):113-23. doi: 10.1111/bjh.13109. Epub 2014 Sep 11.

PMID:
25209873
9.

Prolonged activity of factor IX as a monomeric Fc fusion protein.

Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ.

Blood. 2010 Mar 11;115(10):2057-64. doi: 10.1182/blood-2009-08-239665. Epub 2010 Jan 7.

10.

Emerging drugs for hemophilia B.

Mannucci PM, Franchini M.

Expert Opin Emerg Drugs. 2014 Sep;19(3):407-14. doi: 10.1517/14728214.2014.946010. Epub 2014 Aug 6. Review.

PMID:
25098797
11.

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF.

Blood. 2012 Mar 29;119(13):3031-7. doi: 10.1182/blood-2011-09-382846. Epub 2012 Jan 5.

12.

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.

Toby GG, Liu T, Buyue Y, Zhang X, Bitonti AJ, Pierce GF, Sommer JM, Jiang H, Peters RT.

PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.

13.

Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.

Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B.

Br J Haematol. 2015 Jan;168(1):124-34. doi: 10.1111/bjh.13112. Epub 2014 Sep 11.

PMID:
25208598
14.

Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.

Schulte S.

Thromb Res. 2013 Mar;131 Suppl 2:S2-6. doi: 10.1016/S0049-3848(13)70150-6. Review.

PMID:
23537723
15.

Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.

Ducore JM, Miguelino MG, Powell JS.

Expert Rev Hematol. 2014 Oct;7(5):559-71. doi: 10.1586/17474086.2014.951322. Epub 2014 Aug 21.

PMID:
25142322
17.

Recombinant FIXFc: a novel therapy for the royal disease?

Valentino LA.

Expert Opin Biol Ther. 2011 Oct;11(10):1361-8. doi: 10.1517/14712598.2011.603304. Epub 2011 Jul 22. Review.

PMID:
21780945
18.

Pioneering designs for recombinant coagulation factors.

Schulte S.

Thromb Res. 2011;128 Suppl 1:S9-12. doi: 10.1016/S0049-3848(12)70003-8. Review.

PMID:
22221848
19.

Pharmacokinetics, Safety, and Efficacy of Recombinant Factor VIII Fc Fusion Protein: A Practical Review.

Schafer K, Munn J, Khair K, Thukral N, Tom A, McAlister S.

J Infus Nurs. 2017 Jan/Feb;40(1):65-75. doi: 10.1097/NAN.0000000000000205. Review.

PMID:
28030484
20.

Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.

Miners AH, Krishnan S, Pasi KJ.

J Thromb Haemost. 2016 Nov;14(11):2141-2147. doi: 10.1111/jth.13440. Epub 2016 Oct 3. Erratum in: J Thromb Haemost. 2017 Apr;15(4):829.

PMID:
27510890

Supplemental Content

Support Center